Pharmacokinetics of firocoxib after intravenous administration of multiple consecutive doses in neonatal foals.

This study explores the pharmacokinetic profile of intravenous firocoxib in neonatal foals, revealing a moderate half-life, large volume of distribution at a steady state, and more rapid clearance than seen in adult horses.

Study Objective and Methodology

• The primary objective of this research was to evaluate the pharmacokinetics or the movement of the drug firocoxib in the body of neonatal foals. The focus was on determining the drug’s absorption, distribution, metabolism, and excretion.
• The sample for the study consisted of six healthy foals. These foals were administered 0.09 mg/kg of firocoxib intravenously daily over a period of seven days.
• Blood samples were collected from the foals on several occasions during the study. Initial samples were taken on the first day before the administration of the drug. Subsequent samples were collected at varying hours following each dose, as well as immediately before certain doses. Four final samples were taken at 36, 48, 72, and 96 hours after the last dose.
• The collected samples were analyzed for plasma firocoxib concentration using a method known as high-performance liquid chromatography with fluorescence detection.

Results and Findings

• Noncompartmental analysis of the result was conducted using the trapezoidal method with linear interpolation. This is a mathematical method used in pharmacokinetic studies to calculate different aspects of a drug’s behaviour in the body.
• The results showed that firocoxib has a moderate half-life of around 15.9 ± 9.1 hours in neonatal foals. The half-life of a drug is the time taken for the body to eliminate half of it. In this case, it means that roughly 50% of firocoxib is cleared from the body of neonatal foals in approximately 15.9 hours.
• The study revealed that firocoxib has a high volume of distribution at a steady state in neonatal foals, estimated to be about 1.79 ± 0.57 L/kg. This implies that the drug disperses extensively throughout the tissues of the animal before reaching a steady state of concentration.
• The research also found that the clearance rate of firocoxib in neonatal foals is quite rapid, and indeed faster than what has been observed in adult horses. The cleared amount was calculated to be 96.0 ± 59.2 ml/kg/hour.

Significance of the Research

• The findings of this study provide important insights into the pharmacokinetics of firocoxib in neonatal foals. They lay a basis for developing efficient dosage regimens for this drug in the treatment of medical conditions in young horses.
• The contrast between the clearance rates of the drug in neonatal foals and adult horses suggests that different pharmacological considerations may be required when treating these different groups. This is particularly important to prevent overdose or underdose situations.